Your session is about to expire
← Back to Search
Zimberelimab for Head and Neck Cancers (PANTHEoN Trial)
PANTHEoN Trial Summary
This trial will test the safety of combining two investigational drugs, zimberelimab and etrumadenant, with chemotherapy and radiation to treat head and neck cancer. The study will also look at how the drugs change the microbiome, immune cells, and scarring caused by radiation.
- Head and Neck Cancer
- Throat Cancer
- Oral Cancers
- Oral Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- Oropharyngeal Cancer
- Oropharyngeal Carcinoma
- Laryngeal Cancer
- Hypopharyngeal Cancer
PANTHEoN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 45 Patients • NCT02000531PANTHEoN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received treatment with a medication that targets the adenosine pathway in the past.You have taken certain medications that are processed by a protein called P-glycoprotein (P-gp) and have a narrow range of effectiveness. You must have stopped taking these medications at least 4 weeks ago or 5 times the half-life of the drug, whichever is longer, before starting the study treatment.You have received treatment in the past for head and neck squamous cell carcinoma, including medications, surgeries, or radiation therapy.You have had a heart attack or a blood clot in your arteries within the past few months.You are taking medications that may slow down wound healing or affect blood clotting, like steroids, strong blood thinners, high-dose aspirin, or certain pain relievers.You have received treatment with drugs that help your immune system fight cancer in the past.You have taken certain medications for conditions like high blood pressure or high cholesterol that interact with the study drug within the past month or so.
- Group 1: Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)
- Group 2: Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)
- Group 3: Concurrent Cisplatin/Radiation Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has this medical experiment been embraced by participants?
"This research trial is not presently enrolling patients. The study initiated on February 1st 2023 and was last amended on August 9th 2022. If you are searching for other trials, there exist 3083 clinical studies actively seeking recruits with oral squamous cell carcinoma as well as 689 active investigations involving Zimberelimab in search of participants."
Are enrollees being accepted for this clinical research at present?
"According to clinicaltrials.gov, this particular medical trial has concluded its search for study participants; the initial post was on February 1st 2023 and it closed recruitment as of August 9th 2022. Nevertheless, there are still 3772 other investigations enrolling patients at present."
What indications are Zimberelimab treatments commonly given for?
"Zimberelimab is a commonly-prescribed medication for individuals with advanced ovarian cancer, but it has also been used to treat testicular cancer that does not respond well to standard treatments and advance directives."
Has the Federal Drug Administration sanctioned Zimberelimab?
"There is minimal evidence to support the safety and effectiveness of Zimberelimab, consequently awarding it a score of 1."
What prior research has been conducted into the effects of Zimberelimab?
"Presently, there are 689 active clinical trials which make use of Zimberelimab with 274 in the final phase. Most of these experiments take place inside Shanghai, but 43234 other locations have a presence for this drug as well."
Share this study with friends
Copy Link
Messenger